Cargando…

Nivolumab use for BRCA gene mutation carriers with recurrent epithelial ovarian cancer: A case series

Tumors deficient in DNA mismatch repair are known to display increased susceptibility to immune checkpoint inhibitors due to accumulation of DNA damage and increased neoantigen load. This suggests that deficiency in the BRCA-related DNA repair mechanism may also be a surrogate marker for immunothera...

Descripción completa

Detalles Bibliográficos
Autores principales:	Matsuo, Koji, Spragg, Samantha E., Ciccone, Marcia A., Blake, Erin A., Ricker, Charité, Pham, Huyen Q., Roman, Lynda D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2018
Materias:	Case Series
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6038829/ https://www.ncbi.nlm.nih.gov/pubmed/29998185 http://dx.doi.org/10.1016/j.gore.2018.06.011

Ejemplares similares

Characteristics of ovarian tumors of low malignant potential in BRCA mutation carriers: A case series
por: Matsuo, Koji, et al.
Publicado: (2015)

Evaluation of screening and risk-reducing surgery for women followed in a high-risk breast/ovarian cancer clinic: it is all about the tubes in BRCA mutation carriers
por: Stewart, Martha E., et al.
Publicado: (2019)

Correction to: Adjuvant hysterectomy following primary chemoradiation for stage IB2 and IIA2 cervical cancer: a retrospective comparison of complications for open versus minimally invasive surgery
por: Miller, Heather, et al.
Publicado: (2021)

Adjuvant hysterectomy following primary chemoradiation for stage IB2 and IIA2 cervical cancer: a retrospective comparison of complications for open versus minimally invasive surgery
por: Miller, Heather, et al.
Publicado: (2021)

Patterns and duration of primary and recurrent treatment in ovarian cancer patients with germline BRCA mutations
por: Jorge, Soledad, et al.
Publicado: (2019)

Characteristics of Lynch syndrome in 13 Hispanic Families
por: Ricker, Charite, et al.
Publicado: (2010)

Rhabdomyolysis following single administration of pembrolizumab: Is severe immune-reaction a marker for durable treatment response?
por: Khetan, Varun, et al.
Publicado: (2021)

Molecular Pathways and Targeted Therapies for Malignant Ovarian Germ Cell Tumors and Sex Cord–Stromal Tumors: A Contemporary Review
por: Maoz, Asaf, et al.
Publicado: (2020)

A novel germline BRCA1 mutation identified in a family with hereditary breast and ovarian cancer syndrome
por: Wu, Yanmei, et al.
Publicado: (2021)

Temporal trends and characteristics of suicide among women with gynecologic malignancy in the United States
por: Violette, Caroline J., et al.
Publicado: (2019)

Trends and outcomes of women with synchronous endometrial and ovarian cancer
por: Matsuo, Koji, et al.
Publicado: (2018)

Gastric Cancer Risk and Pathogenesis in BRCA1 and BRCA2 Carriers
por: Buckley, Kole H., et al.
Publicado: (2022)

Endometrioid adenocarcinoma associated with endometrial stromal sarcoma: A rare, often unrecognized collision tumor
por: Kim, Grace, et al.
Publicado: (2015)

Computed tomography imaging findings of nivolumab-induced thyroid dysfunction
por: Oki, Tatsuya, et al.
Publicado: (2022)

PARP inhibitors in BRCA1/BRCA2 germline mutation carriers with ovarian and breast cancer
por: Annunziata, Christina M, et al.
Publicado: (2010)

Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers
por: Zaaijer, Leendert H, et al.
Publicado: (2016)

Nivolumab-induced alopecia areata: A reversible factor of good prognosis?
por: Lakhmiri, Myriam, et al.
Publicado: (2018)

Interstitial lung disease induced by docetaxel and ramucirumab chemotherapy after nivolumab treatment
por: Okeya, Komugi, et al.
Publicado: (2020)

Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations
por: Whittemore, A S, et al.
Publicado: (2004)

Ovarian cancer in BRCA1 and BRCA2 gene mutation carriers: analysis of prognostic factors and survival
por: Biglia, Nicoletta, et al.
Publicado: (2016)

Can chimerism explain breast/ovarian cancers in BRCA non-carriers from BRCA-positive families?
por: Mitchell, Rachel, et al.
Publicado: (2018)

Diagnostic markers for the detection of ovarian cancer in BRCA1 mutation carriers
por: Gschwantler-Kaulich, Daphne, et al.
Publicado: (2017)

Biallelic BRCA Loss and Homologous Recombination Deficiency in Nonbreast/Ovarian Tumors in Germline BRCA1/2 Carriers
por: Wineland, Dylane, et al.
Publicado: (2023)

Co-existence of breast and ovarian cancers in BRCA germ-line mutation carriers
por: Dilawari, A, et al.
Publicado: (2008)

No Sib Pair Concordance for Breast or Ovarian Cancer in BRCA1 Mutation Carriers
por: Møller, Pål, et al.
Publicado: (2007)

Premature ovarian aging in BRCA carriers: a prototype of systemic precocious aging?
por: Ben-Aharon, Irit, et al.
Publicado: (2018)

Correction: Diagnostic markers for the detection of ovarian cancer in BRCA1 mutation carriers
por: Gschwantler-Kaulich, Daphne, et al.
Publicado: (2018)

Breast cancer risk in BRCA mutation carriers after diagnosis of epithelial ovarian cancer is lower than in carriers without ovarian cancer
por: Nañez, Andrea, et al.
Publicado: (2021)

Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers
por: Kuchenbaecker, Karoline B., et al.
Publicado: (2017)

Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants
por: Barnes, Daniel R., et al.
Publicado: (2020)

Trends of uterine carcinosarcoma in the United States
por: Matsuo, Koji, et al.
Publicado: (2018)

Ovarian cancer arising from the proximal fallopian tube in a patient with a BRCA2 mutation
por: Badiner, Nora, et al.
Publicado: (2021)

A case series of triplet anti-hormonal therapy in androgen receptor-positive recurrent adult ovarian granulosa cell tumor()
por: Summey, Rebekah M., et al.
Publicado: (2022)

Time to decide about risk-reducing mastectomy: A case series of BRCA1/2 gene mutation carriers
por: McCullum, Mary, et al.
Publicado: (2007)

Recommendations and Choices for BRCA Mutation Carriers at Risk for Ovarian Cancer: A Complicated Decision
por: Lewis, Kelsey E., et al.
Publicado: (2018)

Association between vitamin D and ovarian cancer development in BRCA1 mutation carriers
por: Pejovic, Tanja, et al.
Publicado: (2020)

Assessing the Variations in Breast/Ovarian Cancer Risk for Chinese BRCA1/2 Carriers
por: Li, Ang, et al.
Publicado: (2022)

BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers
por: Maxwell, Kara N., et al.
Publicado: (2017)

Death of 43 Indonesian women with ovarian cancer: A case series
por: Mulawardhana, Pungky, et al.
Publicado: (2020)

Baseline risk of hematologic malignancy at initiation of frontline PARP inhibitor maintenance for BRCA1/2-associated ovarian cancer
por: Navitski, Anastasia, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_84pm3nckg67stn4dj8iaqp5gb3